|
 |
| home > pmps > summer 2003 > recent technical advances and formulation strategies in pulmonary drug delivery |
|
|
 PUBLICATIONS |
Pharmaceutical Manufacturing and Packing Sourcer
|
Inhalation aerosols have been the subject of significant investment in research and development for almost two decades. At intervals the science and technology have taken leaps forward in response to therapeutic (1, 2) and environmental needs (3). The propellant-driven metered dose inhaler (MDI) has been the dominant inhaler for almost a half century. The combination of the drug dispersed in a high vapour pressure propellant, metered accurately in 10s to 100s of microgram quantities directly to the lungs, was a powerful new tool for the treatment of pulmonary diseases (4). The historical significance of this new technology with potent new therapeutic agents revolutionised the treatment of asthma.
Nebulisers for the delivery of solutions of drugs were in existence prior to the development of the MDI. These systems found their application in acute ambulatory care and domiciliary situations since the droplet size of the aerosol was slightly smaller than that of the MDI, could penetrate more deeply into the lungs of the patients and did not require the degree of co-ordination to effectively deliver the drug (5). Nebulisers continue to have a valuable role in severely compromised patients and for applications other than asthma, notably cystic fibrosis (6).
|
Read full article >>
|
|
 |
|
| Rate this article |
You must be a member of the site to make a vote. |
|
Average rating: |
0 |
| | | | | |
|
|
By Paul J Atkins, CEO, Timothy M Crowder, Chief Technology Officer, Anthony J Hickey, Chief Scientific Officer, Keith A Johnson, Sara A Kraabel and D Dean Mckinney at Oriel Therapeutics Inc
Dr Paul Atkins joined Oriel as its CEO from GlaxoSmithKline where he was involved with the development and commercialisation of inhaled delivery systems, most recently as Director, Delivery Systems in the Global Respiratory Therapeutic Development group. With 18 years' experience in the pharmaceutical industry, Paul's accomplishments include leading a number of global technical development programmes, particularly the development of HFA MDIs. Paul is a Founder of Oriel Therapeutics.
Dr Timothy Crowder is a Founder and Chief Technology Officer of Oriel Therapeutics. His dissertation research, concerning the physics of powder flow and its application to dispersion in dry powder inhalers, forms the basis for Oriel's technology platform. Timm's research at UNC included the direction of an industrially-sponsored nasal dry powder vaccine project and developing a prototype dry powder inhaler with dispersion mechanism.
Professor Anthony Hickey is internationally reputed in the field of inhalation technology and has been a consultant to the pharmaceutical industry for almost 20 years. He is currently Professor in the Division of Drug Delivery and Disposition at the University of North Carolina, Founder and Chief Scientific Officer at Oriel Therapeutics and CEO of Cirrus Pharmaceuticals.
Dr Keith Johnson has over 15 years of pharmaceutical industry experience, which includes development of formulations and delivery systems for small molecules, peptides, and proteins. In addition to several patents, he has written and lectured on colloid and interface science, respiratory drug delivery, topical drug delivery and experimental design.
At Oriel, Ms Sara Kraabel is employed in pharmaceutical powder characterisation and evaluation of Oriel's prototype inhaler. She has previous experience in clinical data management in CROs such as Quintiles Transnational Corp and PPD Inc, as well as medical device development in the area of semi-invasive blood glucose monitors.
Mr D Dean McKinney has been employed in pharmaceutical and health care-related industries for over 21 years. Before recently beginning a new career in pharmaceutical business development consulting, he served as Vice President of Business Development for Bespak Inc. In his prior position he was involved with commercial and manufacturing operations of pulmonary and nasal drug delivery technologies.
|
|
|
|
|
|
 |
Industry Events |
 |
4th Annual Patient Recruitment and Retention in Clinical Trials
13-15 October 2008, Amsterdam
Patient recruitment
is now consuming thirty percent of clinical trial time - more time than any
other clinical trial activity - and almost half of all trial delays result from
patient recruitment problems.
As the
recruiting culture becomes more sophisticated and the forces affecting patient
enrollment grow more numerous and complex, pharmaceutical companies are
striving to discover new strategies to facilitate enrollment in clinical
trials.
With
increasing industry pressure to develop, test and market greater numbers of new
drugs faster, pharmaceutical companies need to perform clinical trials as
quickly as possible. Inefficient patient recruitment processes is a formidable
barrier to pharmaceutical companies' success in launching new products.
Improving the patient recruitment process is imperative to avoid wasted
investments and eliminate costly delays in bringing new drugs to market --
today and even more so in the not-so-distant future. Improved patient
recruitment presents one of the largest opportunities for pharmaceutical
companies to eliminate delays in clinical trials, thereby making it possible to
reduce time to market. With patent time limits and large overheads
meaning that any delays in the development timeline can be disastrous, a good
understanding of how to successfully recruit patients for trials is vital for
any company looking to succeed.
More info >> |
|
 |
News and Press Releases |
 |
“PACK DIFFERENT” with EMBALLAGE 2008
“Business, Innovation, Outlook” are the watchwords for the 38th World Packaging Exhibition which opens in Paris from 17 to 21 November 2008. Fifteen months before the key packaging event of the end of 2008, EMBALLAGE displays its differences to offer you a new edition that is even more representative, international and rich in new features.
More info >> |
|
 |
